Novartis gets FDA approval for lutetium Lu 177 dotatate (Lutathera) for pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
- Lutetium Lu 177 dotatate received approval for this indication for adults in 2018
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2024 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.